Leucine-rich repeat kinase 2 (LRRK2) cellular biology: A review of recent advances in identifying physiological substrates and cellular functions

Journal of Neurogenetics

Volumn 25, Issue 4, 2011, Pages 140-151

  Drolet, Robert E ^a   Sanders, John M ^a   Kern, Jonathan T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

14 3 3; 4E BP; Futsch; Parkinson's disease

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GUANOSINE TRIPHOSPHATASE; INITIATION FACTOR 4E; LEUCINE RICH REPEAT KINASE 2; STRESS ACTIVATED PROTEIN KINASE;

AMINO TERMINAL SEQUENCE; AUTOPHOSPHORYLATION; CARBOXY TERMINAL SEQUENCE; CELL COMPARTMENTALIZATION; CELL FUNCTION; CHROMOSOME 12; DEPOLYMERIZATION; DISEASE ASSOCIATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE LOCUS; GENE MUTATION; GENOTYPE; HUMAN; INHIBITION KINETICS; MOLECULAR DYNAMICS; NEUROMUSCULAR SYNAPSE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYTOSKELETAL PROTEINS; HUMANS; NEURONS; PARKINSON DISEASE; PROTEIN BIOSYNTHESIS; PROTEIN MODIFICATION, TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; SUBSTRATE SPECIFICITY;

EID: 81555205691     PISSN: 01677063     EISSN: 15635260     Source Type: Journal    
DOI: 10.3109/01677063.2011.627072     Document Type: Review

References (57)

1. Andres-Mateos, E., Mejias, R., Sasaki, M., Li, X., Lin, B. M., Biskup, S., Zhang, L., Banerjee, R., Thomas, B., Yang, L., Liu, G., Beal, M. F., Huso, D. L., Dawson T. M., & Dawson V. L. (2009). Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine). J Neurosci, 29, 15846-15850.
2. Bonifati, V. (2007). LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem Res 32, 1700-1708.
3. Chartier-Harlin, M. C., Dachsel, J. C., Vilarino-Guell, C., Lincoln, S. J., Lepretre, F., Hulihan, M. M., Kachergus, J., Milnerwood, A. J., Tapia, L., Song, M. S., Le Rhun, E., Mutez, E., Larvor, L., Dufl ot, A., Vanbesien-Mailliot, C., Kreisler, A., Ross, O. A., Nishioka, K., Soto-Ortolaza, A. I., Cobb, S. A., Melrose, H. L., Behrouz, B., Keeling, B. H., Bacon, J. A., Hentati, E., Williams, L., Yanagiya, A., Sonenberg, N., Lockhart, P. J., Zubair, A. C., Uitti, R. J., Aasly, J. O., Krygowska-Wajs, A., Opala, G., Wszolek, Z. K., Frigerio, R., Maraganore, D. M., Gosal, D., Lynch, T., Hutchinson, M., Bentivoglio, A. R., Valente, E. M., Nichols, W. C., Pankratz, N., Foroud, T., Gibson, R. A., Hentati, F., Dickson, D. W., Destee, A., & Farrer, M. J. (2011). Translation initiator EIF4G1 mutations in familial parkinson disease. Am J Hum Genet 89, 398-406.
4. Correia Guedes, L., Ferreira, J. J., Rosa, M. M., Coelho, M., Bonifati, V., & Sampaio, C. (2010). Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review. Parkinsonism Relat Disord 16, 237-242.
5. Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J. D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., & Gray, N. S. (2011). Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 7, 203-205.
6. Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifi tto, G., Siderowf, A., & Tanner, C. M. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through, 2030. Neurology 68, 384-386.
7. Dzamko, N., Deak, M., Hentati, F., Reith, A. D., Prescott, A. R., Alessi, D. R., & Nichols, R. J. (2010). Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem 430, 405-413.
8. Fadden, P., Haystead, T. A., & Lawrence, J. C., Jr. (1997). Identifi cation of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. J Biol Chem 272, 10240-10247.
9. Fu, H., Subramanian, R. R., & Masters, S. C. (2000). 14-3-3 proteins: Structure, function, and regulation. Annu Rev Pharmacol Toxicol 40, 617-647.
10. Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., & Obata, F. (2002). A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51, 296-301.
11. Gingras, A. C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch- Cieszynska, A., Aebersold, R., & Sonenberg, N. (2001). Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15, 2852-2864.
12. Gloeckner, C. J., Schumacher, A., Boldt, K., & Ueffi ng, M. (2009). The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem 109, 959-968.
13. Greggio, E., Taymans, J. M., Zhen, E. Y., Ryder, J., Vancraenenbroeck, R., Beilina, A., Sun, P., Deng, J., Jaffe, H., Baekelandt, V., Merchant, K., & Cookson, M. R. (2009). The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 389, 449-454.
14. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., Ahmad, R., Miller, D. W., Kesavapany, S., Singleton, A., Lees, A., Harvey, R. J., Harvey, K., & Cookson, M. R. (2006). Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329-341.
15. Halpain, S., & Dehmelt, L. (2006). The MAP1 family of microtubule-associated proteins. Genome Biol 7, 224.
16. Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., Ferreira, J. J., Tolosa, E., Kay, D. M., Klein, C., Williams, D. R., Marras, C., Lang, A. E., Wszolek, Z. K., Berciano, J., Schapira, A. H., Lynch, T., Bhatia, K. P., Gasser, T., Lees, A. J., & Wood, N. W. (2008). Phenotype, genotype, and worldwide genetic penetrance of LRRK2- associated Parkinson's disease: A case-control study. Lancet Neurol 7, 583-590.
17. Heesom, K. J., Avison, M. B., Diggle, T. A., & Denton, R. M. (1998). Insulin-stimulated kinase from rat fat cells that phosphorylates initiation factor 4E-binding protein 1 on the rapamycin-insensitive site (serine-111). Biochem J 336 (Pt l), 39-48.
18. Hudkins, R. L., Diebold, J. L., Tao, M., Josef, K. A., Park, C. H., Angeles, T. S., Aimone, L. D., Husten, J., Ator, M. A., Meyer, S. L., Holskin, B. P., Durkin, J. T., Fedorov, A. A., Fedorov, E. V., Almo, S. C., Mathiasen, J. R., Bozyczko- Coyne, D., Saporito, M. S., Scott, R. W., & Mallamo, J. P. (2008). Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c] carbazole-5-ones: Optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4- phenyltetrahydropyridine models. J Med Chem 51, 5680-5689.
19. Hummel, T., Krukkert, K., Roos, J., Davis, G., & Klambt, C. (2000). Futsch/22C10 is a MAP1B-like protein required or dendritic and axonal development. Neuron 26, 357-370.
20. Imai, Y., Gehrke, S., Wang, H. Q., Takahashi, R., Hasegawa, K., Oota, E., & Lu, B. (2008). Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in . Drosophila. EMBO J 27, 2432-2443.
21. Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011). Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell 42, 9-22.
22. Kamikawaji, S., Ito, G., & Iwatsubo, T. (2009). Identifi cation of the autophosphorylation sites of LRRK2. Biochemistry 48, 10963-10975.
23. Kumar, A., Greggio, E., Beilina, A., Kaganovich, A., Chan, D., Taymans, J. M., Wolozin, B., & Cookson, M. R. (2010). The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 5, e8730.
24. Lee, S., Liu, H. P., Lin, W. Y., Guo, H., & Lu, B. (2010). LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the neuromuscular junction. J Neurosci 30, 16959-16969.
25. Li, X., Wang, Q. J., Pan, N., Lee, S., Zhao, Y., Chait, B. T., & Yue, Z. (2011). Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 6, e17153.
26. Liao, X. H., Majithia, A., Huang, X., & Kimmel, A. R. (2008). Growth control via TOR kinase signaling, an intracellular sensor of amino acid and energy availability, with crosstalk potential to proline metabolism. Amino Acids 35, 761-770.
27. Marras, C., Schuele, B., Munhoz, R. P., Rogaeva, E., Langston, J. W., Kasten, M., Meaney, C., Klein, C., Wadia, P. ., Lim, S. Y., Chuang, R. S., Zadikof, C., Steeves, T., Prakash, K. M., de Bie, R. M., Adeli, G., Thomsen, T., Johansen, K. K., Teive, H. A., Asante, A., Reginold, W., & Lang, A. E. (2011). Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 77, 325-333.
28. Matus, A. (1991). Microtubule-associated proteins and neuronal morphogenesis. J Cell Sci Suppl 15, 61-67.
29. Melrose, H. L., Dachsel, J. C., Behrouz, B., Lincoln, S. J., Yue, M., Hinkle, K. M., Kent, C. B., Korvatska, E., Taylor, J. P., Witten, L., Liang, Y. Q., Beevers, J. E., Boules, M., Dugger, B. N., Serna, V. A., Gaukhman, A., Yu, X., Castanedes- Casey, M., Braithwaite, A. T., Ogholikhan, S., Yu, N., Bass, D., Tyndall, G., Schellenberg, G. D., Dickson, D. W., Janus, C., & Farrer, M. J. (2010). Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40, 503-517.
30. Morrison, D. K. (2009). The 14-3-3 proteins: Integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 19 , 16-23.
31. Nalls, M. A., Plagnol, V., Hernandez, D. G., Sharma, M., Sheerin, U. M., Saad, M., Simon-Sanchez, J., Schulte, C., Lesage, S., Sveinbjornsdottir, S., Stefansson, K., Martinez, M., Hardy, J., Heutink, P., Brice, A., Gasser, T., Singleton, A. B., & Wood, N. W. (2011). Imputation of sequence variants for identifi cation of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377, 641-649.
32. Nichols, R. J., Dzamko, N., Morrice, N. A., Campbell, D. G., Deak, M., Ordureau, A., Macartney, T., Tong, Y., Shen, J., Prescott, A. R., & Alessi, D. R. (2010). 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's diseaseassociated mutations and regulates cytoplasmic localization. Biochem J 430, 393-404.
33. Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A. M., Khan, N., Johnson, J., Martinez, J. R., Nicholl, D., Carrera, I. M., Pena, A. S., de Silva, R., Lees, A., Marti- Masso, J. F., Perez-Tur, J., Wood, N. W., & Singleton, A. B. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
34. Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., & Regan, J. (2002). Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9, 268-272.
35. Parisiadou, L., Xie, C., Cho, H. J., Lin, X., Gu, X. L., Long, C. X., Lobbestael, E., Baekelandt, V., Taymans, J. M., Sun, L., & Cai, H. (2009). Phosphorylation of ezrin/radixin/ moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29, 13971-13980.
36. Pyronnet, S., Imataka, H., Gingras, A. C., Fukunaga, R., Hunter, T., & Sonenberg, N. (1999). Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J 18, 270-279.
37. Ramonet, D., Daher, J. P., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., Liu, Y., Swing, D. A., Beal, M. F., Troncoso, J. C., McCaffery, J. M., Jenkins, N. A., Copeland, N. G., Galter, D., Thomas, B., Lee, M. K., Dawson, T. M., Dawson, V. L., & Moore, D. J. (2011). Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 6, e18568.
38. Rhoads, R. E. (2009). eIF4E: New family members, new binding partners, new roles. Biol Chem 284, 16711-16715.
39. Roos, J., Hummel, T., Ng, N., Klambt, C., & Davis, G. W. (2000). Futsch regulates synaptic microtubule organization and is necessary for synaptic growth. Neuron 26, 371-382.
40. Ross, O. A., Soto-Ortolaza, A. I., Heckman, M. G., Aasly, J. O., Abahuni, N., Annesi, G., Bacon, J. A., Bardien, S., Bozi, M., Brice, A., Brighina, L., Van Broeckhoven, C., Carr, J., Chartier- Harlin, M. C., Dardiotis, E., Dickson, D. W., Diehl, N. N., Elbaz, A., Ferrarese, C., Ferraris, A., Fiske, B., Gibson, J. M., Gibson, R., Hadjigeorgiou, G. M., Hattori, N., Ioannidis, J. P., Jasinska-Myga, B., Jeon, B. S., Kim, Y. J., Klein, C., Kruger, R., Kyratzi, E., Lesage, S., Lin, C. H., Lynch, T., Maraganore, D. M., Mellick, G. D., Mutez, E., Nilsson, C., Opala, G., Park, S. S., Puschmann, A., Quattrone, A., Sharma, M., Silburn, P. A., Sohn, Y. H., Stefanis, L., Tadic, V., Theuns, J., Tomiyama, H., Uitti, R. J., Valente, E. M., van de Loo, S., Vassilatis, D. K., Vilarino-Guell, C., White, L. R., Wirdefeldt, K., Wszolek, Z. K., Wu, R. M., & Farrer, M. J. (2011). Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: A case-control study. Lancet Neurol
41. Rudenko, I. N., & Cookson, M. R. (2010). 14-3-3 proteins are promising LRRK2 interactors. Biochem J 430, e5-e6.
42. Saha, S., Guillily, M. D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Hsu, C. H., Segal, L., Raghavan, K., Matsumoto, K., Hisamoto, N., Kuwahara, T., Iwatsubo, T., Moore, L., Goldstein, L., Cookson, M., & Wolozin, B. (2009). LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29, 9210-9218.
43. Saunders-Pullman, R., Stanley, K., Wang, C., San Luciano, M., Shanker, V., Hunt, A., Severt, L., Raymond, D., Ozelius, L. J., Lipton, R. B., & Bressman, S. B. (2011). Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 77, 319-324.
44. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938-1942.
45. Schoenfeld, T. A., & Obar, R. A. (1994). Diverse distribution and function of fi brous microtubule-associated proteins in the nervous system. Int Rev Cytol 151, 67-137.
46. Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. O., Dror, R. O., Kuriyan, J., & Shaw, D. E. (2009). A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A106, 139-144.
47. Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011). Parkinson's disease: Genetics and pathogenesis. Annu Rev Pathol 6, 193-222.
48. Tain, L. S., Mortiboys, H., Tao, R. N., Ziviani, E., Bandmann, O., & Whitworth, A. J. (2009). Rapamycin activation of 4EBP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 12, 1129-1135.
49. Teleman, A. A., Chen, Y. W., & Cohen, S. M. (2005). 4E-BP functions as a metabolic brake used under stress conditions but not during normal growth. Genes Dev 19 , 1844-1848.
50. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., 3rd, & Shen, J. (2010). Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 107, 9879-9884.
51. Van Den Eeden, S. K., Tanner, C. M., Bernstein, A. L., Fross, R. D., Leimpeter, A., Bloch, D. A., & Nelson, L. M. (2003). Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am J Epidemiol 157, 1015-1022.
52. Vandecandelaere, A., Pedrotti, B., Utton, M. A., Calvert, R. A., & Bayley, P. M. (1996). Differences in the regulation of microtubule dynamics by microtubule-associated proteins MAP1B and MAP2. Cell Motil Cytoskeleton 35, 134-146.
53. Wang, D., Tang, B., Zhao, G., Pan, Q., Xia, K., Bodmer, R., & Zhang, Z. (2008). Dispensable role of ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener 3, 3.
54. Webber, P. J., Smith, A. D., Sen, S., Renfrow, M. B., Mobley, J. A., & West, A. B. (2011). Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifi es kinase and GTP-binding activities. J Mol Biol 412, 94-110.
55. Westerlund, M., Belin, A. C., Anvret, A., Bickford, P., Olson, L., & Galter, D. (2008). Developmental regulation of leucinerich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. Neuroscience 152, 429-436.
56. Zhou, H., Huang, C., Tong, J., Hong, W. C., Liu, Y. J., & Xia, X. G. (2011). Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci 7, 753-761.
57. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., Stoessl, A. J., Pfeiffer, R. F., Patenge, N., Carbajal, I. C., Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D. W., Meitinger, T., Strom, T. M., Wszolek, Z. K., & Gasser, T. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607.